Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

Maze Therapeutics, Inc.’s MAZE share price has surged by 11.03%, which has investors questioning if this is right time to ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

A scientific statement regarding disparities in current pulmonary embolism management and outcomes has been published by the AHA.